CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah

Featuring an interview with Dr Bijal Shah, including the following topics: Advent and importance of blinatumomab in the therapeutic landscape of acute lymphoblastic leukemia (ALL) (0:00) Similarities and differences between bispecific T-cell engagers (BiTEs) and bispecific antibodies (5:51) Rationale underlying the development of surovatamig and MK-1045; benefits of blinatumomab for patients without detectable minimal residual disease (9:56) Extramedullary ALL, including in the CNS (13:32) Key principles in the development and use of surovatamig and MK-1045, including structural features and recent efficacy and safety findings (18:34) Ongoing immunotherapy trials for ALL, including studies of BiTEs and chimeric antigen receptor T-cell therapy (25:37) Case: A woman in her late 50s with newly diagnosed Philadelphia chromosome-positive B-cell ALL and multiple comorbidities (31:48) Case: A woman in her early 50s with newly diagnosed B-cell ALL, a TP53 mutation and significant extramedullary disease including the CNS (41:16) Case: A man in his early 50s with intermediate-risk B-cell ALL who receives surovatamig on a clinical trial (53:05) CME information and select publications